1. Home
  2. FTK vs DSGN Comparison

FTK vs DSGN Comparison

Compare FTK & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Flotek Industries Inc.

FTK

Flotek Industries Inc.

HOLD

Current Price

$16.84

Market Cap

522.1M

Sector

Industrials

ML Signal

HOLD

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

SELL

Current Price

$10.11

Market Cap

579.9M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
FTK
DSGN
Founded
1985
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
522.1M
579.9M
IPO Year
1997
2021

Fundamental Metrics

Financial Performance
Metric
FTK
DSGN
Price
$16.84
$10.11
Analyst Decision
Buy
Strong Buy
Analyst Count
1
4
Target Price
$20.00
$15.25
AVG Volume (30 Days)
280.8K
247.6K
Earning Date
03-11-2026
03-09-2026
Dividend Yield
N/A
N/A
EPS Growth
147.06
N/A
EPS
0.84
N/A
Revenue
$136,092,000.00
N/A
Revenue This Year
$11.40
N/A
Revenue Next Year
$18.40
N/A
P/E Ratio
$19.65
N/A
Revenue Growth
214.53
N/A
52 Week Low
$6.05
$2.62
52 Week High
$20.41
$11.23

Technical Indicators

Market Signals
Indicator
FTK
DSGN
Relative Strength Index (RSI) 49.92 49.12
Support Level $16.25 $9.64
Resistance Level $17.12 $11.14
Average True Range (ATR) 1.47 0.60
MACD 0.03 0.00
Stochastic Oscillator 35.53 34.09

Price Performance

Historical Comparison
FTK
DSGN

About FTK Flotek Industries Inc.

Flotek Industries Inc is a technology-driven specialty chemistry and data company. It has two reportable segments: Its Chemistry Technologies segment includes specialty chemistries, logistics and technology services. It also include integrated oil and gas companies, oilfield services companies, independent oil and gas companies, national and state-owned oil companies, and international supply chain management companies. The Data Analytics segment provides analytical measurement solutions and deliver real-time information and insights to customers to enable optimization of operations and reduction of emissions and their carbon intensity. Key revenue comes from its Chemistry Technologies segment.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

Share on Social Networks: